PIDTC Project 6907 SCID ? Abstract Severe Combined Immunodeficiency Disease (SCID) is a genetically heterogeneous group of disorders leading to defects in T and B cell numbers or function. Our combined prospective (Protocol 6901) and retrospective (Protocol 6902) studies implemented during the 1st two grant cycles now include >750 surviving SCID patients, which will be further augmented with additional newly diagnosed patients from 44 US and Canadian PIDTC Centers during this grant cycle (Protocol 6907). Newborn screened (NBS) patients represent a high percentage of the SCID cohort, and now predominate in the USA and parts of Canada. Our prior studies have shown that: 1) ~7% of SCID cases have no identified genotype; 2) infection remains a major issue even in SCID diagnosed via NBS; 3) there are major gaps in our knowledge of hematopoietic cell transplant (HCT)- related late effects and health-related quality of life (HR-QoL); 4) while genotype strongly impacts overall survival (OS) and immune reconstitution, genotypic-specific approaches to optimize outcomes have not been defined; 5) CD4+ and nave CD4+ T cell counts as early as 6 months post HCT predict long-term OS and immune reconstitution. These results have fueled the design and implementation of a prospective randomized trial exploring intensity of conditioning infants with SCID (NCT03619551). We propose that prospective enrollment of new cases plus extended follow-up of those previously enrolled will create an unparalleled resource for robust analysis of the SCID management and diagnosis approaches. While HCT treatment approaches are selected by individual centers, comprehensive, longitudinal data from this large PIDTC cohort will permit comparative assessment of outcomes beyond OS that will generate questions we will address in multicenter prospective SCID treatment trials. The objective of this proposal is to advance the understanding, diagnosis, management, and treatment of SCID in order to define how best to optimize survival and achieve full immune reconstitution after allogeneic HCT or autologous gene therapy (GT). With our large cohort we will: 1) identify unknown genes and functional defects in T cell development; 2) associate genotype and chemotherapy exposure in infancy with post-HCT late effects; 3) assess long-term outcomes of patients with SCID diagnosed by NBS and treated at a very young age (<6 months); 4) assess HR-QoL and patient reported outcomes (PROs); 5) further characterize the incidence and clinical associations of T cell exhaustion post- HCT, further defining early post HCT biomarkers to predict OS and immune reconstitution so that interventions can be designed to avoid rejection and/or enhance immune recovery; 6) determine which patients should receive GT with autologous modified hematopoietic cells, and 7) explore the incidence and reasons for pre- HCT viral infections in NBS SCID infants to propose clinical trials for prevention. The additional impact of the proposed research is that the longitudinal natural history and mechanistic studies we perform will generate hypotheses that translate into practice-changing clinical trials for SCID patients.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Chinen, Javier; Cowan, Morton J (2018) Advances and highlights in primary immunodeficiencies in 2017. J Allergy Clin Immunol 142:1041-1051
Miggelbrink, Alexandra M; Logan, Brent R; Buckley, Rebecca H et al. (2018) B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood 131:2967-2977
Slack, James; Albert, Michael H; Balashov, Dmitry et al. (2018) Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders. J Allergy Clin Immunol 141:322-328.e10
Langelier, Charles; Zinter, Matt S; Kalantar, Katrina et al. (2018) Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients. Am J Respir Crit Care Med 197:524-528
Haddad, Elie; Logan, Brent R; Griffith, Linda M et al. (2018) SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery. Blood 132:1737-1749
Barzaghi, Federica; Amaya Hernandez, Laura Cristina; Neven, Benedicte et al. (2018) Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. J Allergy Clin Immunol 141:1036-1049.e5
Kuo, Caroline Y; Long, Joseph D; Campo-Fernandez, Beatriz et al. (2018) Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome. Cell Rep 23:2606-2616
Belderbos, Mirjam E; Gennery, Andrew R; Dvorak, Christopher C et al. (2018) Outcome of domino hematopoietic stem cell transplantation in human subjects: An international case series. J Allergy Clin Immunol 142:1628-1631.e4
Buchbinder, David; Smith, Matthew J; Kawahara, Misako et al. (2018) Application of a radiosensitivity flow assay in a patient with DNA ligase 4 deficiency. Blood Adv 2:1828-1832
Kohn, Donald B; Hershfield, Michael S; Puck, Jennifer M et al. (2018) Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol :

Showing the most recent 10 out of 88 publications